<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006034</url>
  </required_header>
  <id_info>
    <org_study_id>INTRACEL-BCI-9804-04</org_study_id>
    <secondary_id>CDR0000068047</secondary_id>
    <nct_id>NCT00006034</nct_id>
  </id_info>
  <brief_title>Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer</brief_title>
  <official_title>A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intracel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies use different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells&#xD;
      from dividing so they stop growing or die. It is not yet known whether keyhole limpet&#xD;
      hemocyanin is more effective than doxorubicin for bladder cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of keyhole limpet hemocyanin&#xD;
      with that of doxorubicin in treating patients who have bladder cancer that has not responded&#xD;
      to BCG or in those patients who cannot tolerate BCG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of BCI-ImmuneActivatorâ„¢ (keyhole limpet hemocyanin) versus&#xD;
           doxorubicin in BCG refractory or intolerant patients with carcinoma in situ with or&#xD;
           without resected superficial papillary bladder cancer.&#xD;
&#xD;
        -  Compare the toxicity and safety of these treatments in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center and prior BCG response (refractory vs intolerant). Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH)&#xD;
           intradermally at week -2 followed by induction KLH IV once weekly at weeks 1-6. Patients&#xD;
           with partial or no response receive IV KLH reinduction therapy once weekly at weeks&#xD;
           13-18. Patients with complete response receive IV KLH maintenance therapy monthly at&#xD;
           weeks 13, 17, and 21, and then at months 6-12.&#xD;
&#xD;
        -  Arm II: Patients receive doxorubicin IV once weekly at weeks 1-6. Patients with complete&#xD;
           response receive maintenance therapy comprising doxorubicin IV at weeks 13, 17, and 21&#xD;
           and months 6-12.&#xD;
&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1.5 years, and then every 6 months for 1 year.&#xD;
      (Patient total participation in this study may last as long as 42 months.)&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 150 patients (75 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH) intradermally in week 2 followed by induction KLH IV once weekly in weeks 1-6. Patients with partial or no response receive IV KLH reinduction therapy once weekly in weeks 13-18. Patients with complete response receive IV KLH maintenance therapy monthly in weeks 13, 17, and 21, and then in months 6-12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive doxorubicin IV once weekly in weeks 1-6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>keyhole limpet hemocyanin</intervention_name>
    <description>Given intradermally and IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed carcinoma in situ of the bladder with or&#xD;
             without resected superficial papillary tumor&#xD;
&#xD;
               -  Biopsy within 3 months of study with or without positive urinary cytology within&#xD;
                  6 weeks of study&#xD;
&#xD;
          -  Cystoscopy within 3 months of study&#xD;
&#xD;
          -  Negative imaging study of the ureters and kidneys within 6 months of study&#xD;
&#xD;
          -  BCG refractory disease&#xD;
&#xD;
               -  Received and failed at least 1 prior induction course consisting of BCG weekly&#xD;
                  for 6 weeks OR&#xD;
&#xD;
          -  BCG intolerant&#xD;
&#xD;
               -  Unable to receive an adequate course of intravesical BCG due to extreme toxicity&#xD;
&#xD;
          -  Opted against or medically contraindicated to cystectomy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC greater than 4,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 11 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT/SGPT normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times upper limit of normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No severe cardiovascular disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other severe disease&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal or squamous cell skin cancer&#xD;
             or noninvasive cancer of the cervix&#xD;
&#xD;
          -  No evidence of autoimmune disease, known immune deficiency, or immunosuppression&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior keyhole limpet hemocyanin immune activator&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior doxorubicin&#xD;
&#xD;
          -  At least 3 months since prior mitomycin&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 months since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior intravesical therapy&#xD;
&#xD;
          -  At least 3 months since prior investigational agents&#xD;
&#xD;
          -  No concurrent cytotoxic immunosuppressive agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael G Hanna Jr., PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Intracel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intracel Resources, LLC</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Keyhole-limpet hemocyanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

